EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A bovine in vitro platform improves species comparability of mitochondrial apoptosis drug-response readouts

Frederike Werry, Axel Schöniger, Annett Honak, Janett Fischer, Paula Richter, Frank Edlich

Archives of Toxicology · 2026

DOI: 10.1007/s00204-026-04506-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archives of Toxicology, 2026. Verfasst von Frederike Werry und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Veterinary Medicine, Institute of Biochemistry, University of Leipzig, 04103, Leipzig, Germany. Hauptthemen laut MEDLINE: Apoptosis, Hepatocytes, Mitochondria, Mitochondria, Liver. Die Arbeit nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universität Leipzig.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Species differences in mitochondrial apoptosis control can bias cytotoxicity endpoints and hazard-relevant mechanistic inference in preclinical test systems that rely on intrinsic-apoptosis readouts. We benchmarked steady-state localization and outer mitochondrial membrane (OMM) assemblies of the BCL-2 effectors BAX and BAK across mammals and combined this with functional apoptosis assays in bovine hepatocytes. Across species, bovine cells most closely recapitulated the human baseline state, whereas murine systems displayed distinct BAX/BAK partitioning and reduced capture of mitochondrial BAX in high-molecular-weight OMM assemblies. Functionally, bovine BFH12 cells showed minimal apoptotic response to the BH3 mimetic ABT-737 as a single agent, while responding robustly to doxorubicin and actinomycin D, as assessed by cytochrome c release, caspase processing and activity, and Annexin V/PI cytometry. These findings identify species-dependent regulation of BAX/BAK retrotranslocation and OMM assembly states as a baseline variable that shapes intrinsic-apoptosis pharmacodynamics. Incorporating bovine systems as a complementary non-rodent in vitro platform may improve model selection and pharmacodynamic readouts for compounds expected to engage mitochondrial apoptosis, thereby reducing avoidable translational misclassification in apoptosis-focused pipelines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ApoptosisHepatocytesMitochondriaMitochondria, LiverAnimalsCattlebcl-2 Homologous Antagonist-Killer Proteinbcl-2-Associated X ProteinSpecies SpecificityHumansMiceMitochondrial MembranesDactinomycinCytochromes cCell LineDoxorubicin

Stichwörter der Autor:innen

BAKBAXIntrinsic apoptosisOuter mitochondrial membrane (OMM)Retrotranslocation

Substanzen

bcl-2 Homologous Antagonist-Killer Proteinbcl-2-Associated X ProteinDactinomycinCytochromes cDoxorubicin

Autor:innen und Institutionen

  • Faculty of Veterinary Medicine, Institute of Biochemistry, University of Leipzig, 04103, Leipzig, Germany.
  • Section of Hepatology, Department of Gastroenterology and Rheumatology, University Hospital Leipzig, Leipzig, Germany.
  • Faculty of Veterinary Medicine, Institute of Biochemistry, University of Leipzig, 04103, Leipzig, Germany. frank.edlich@vetmed.uni-leipzig.de.

Förderung

  • Universität Leipzig

Zitieren

APA

Werry, F., Schöniger, A., Honak, A., Fischer, J., Richter, P., & Edlich, F. (2026). A bovine in vitro platform improves species comparability of mitochondrial apoptosis drug-response readouts. Archives of Toxicology. https://doi.org/10.1007/s00204-026-04506-9

Vancouver

Werry F, Schöniger A, Honak A, Fischer J, Richter P, Edlich F. A bovine in vitro platform improves species comparability of mitochondrial apoptosis drug-response readouts. Archives of Toxicology. 2026. doi:10.1007/s00204-026-04506-9

BibTeX
@article{Werry2026,
  author = {Werry, Frederike and Schöniger, Axel and Honak, Annett and Fischer, Janett and Richter, Paula and Edlich, Frank},
  title = {A bovine in vitro platform improves species comparability of mitochondrial apoptosis drug-response readouts},
  journal = {Archives of Toxicology},
  year = {2026},
  doi = {10.1007/s00204-026-04506-9}
}
Kostenlos starten →